Results

1–10 of 16 results for Dry AMD (non-neovascular)

Dual Anti-platelet Therapy Decelerates the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Yodpong Chantarasorn, MD
On Demand Cases, Courses, and Papers
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Machine Learning Enabled Outer Retinal OCT Biomarker Extraction for Identification of High-Risk AMD Eyes for Subfoveal Geographic Atrophy Progression
Kubra Sarici, MD
Annual Meeting Talks
2021
Efficacy and Safety of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda System (LIGHTSITE III Interim Analysis)
Richard B. Rosen, MD, DSc(Hon), FACS, FASRS, FARVO
Updates from the Field
2022
Impact of Baseline OCT Characteristics on Response to Risuteganib for the Treatment of Intermediate Age-Related Macular Degeneration
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2020
Therapeutic Horizons for Dry AMD
Robert L. Avery, MD
Updates from the Field
2019
Performance and Usability of a Self-Operated Home Optical Coherence Tomography (OCT) System: NOTAL-OCT V2.5 (NO V2.5)
Judy E. Kim, MD, FASRS
Annual Meeting Talks
2019
Associations Between Perifoveal Drusen Burden and Genetic Risk in Eyes With Early or Intermediate Age-Related Macular Degeneration
Johanna M. Seddon, MD, ScM, FARVO, FASRS
Annual Meeting Talks
2019
Frequency of Age-Related Macular Degeneration Risk Alleles Y402H and A69S in a Direct-to-Consumer Genetic Database
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2019
Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019